Here are seven things to know:
1. Although the OsteoCool System was originally only cleared for use in the spine, the FDA has now cleared it to be used as a palliative treatment of metastases in all bones for patients who haven’t benefited from standard therapies.
2. The system uses targeted radiofrequency energy to remove malignant metastatic bone tumors. The expanded clearance will most likely impact the system’s use on rib, sacrum, extremity and hip treatment.
3. Sandeep Bagla, MD, of the Vascular Institute of Virginia in Woodbridge, Va., says: “With the expanded indication for the OsteoCool System, I now have the option to ablate…patients’ painful bone tumors when conventional therapies are considered ineffective, too slow-acting or cause unacceptable side effects.”
4. Approximately 60 to 80 percent of cancer patients have metastatic bone disease, with the ailment most often affecting patients with primary malignancies of the breast, prostate, liver and lung.
5. Over 80 percent of bone metastases occur in skull, spine and ribs.
6. Medtronic acquired the OsteoCool technology from Montreal-based Baylis Medical in 2015 and partnered with the Canadian company to continue improving the system.
7. OsteoCool is temperature controlled and prevents overheating of surrounding tissues during the procedure thanks to internal water-cooled probes.
More device articles:
FDA clears Centric Medical’s Metatarsal Hemi Implant System — 5 details
3-D printing for medical sector to grow at 11.7% CAGR through 2024: 5 notes
Curt Wiedenhoefer named president of Consensus Orthopedics — 4 details
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
